Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05931276 · ClinicalTrials.gov registry record · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
A Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,540
- Enrollment target
- 8
- Study locations
NCT05931276: Recruiting Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by VA Office of Research and Development.
NCT05931276 is a Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 2,540 participants, above the 804-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (216% higher). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05931276, a Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,540 participants
- Enrollment target
- 8
- Study locations
Study Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Primary Outcome
The Primary outcome measure will be time to a non-fatal adverse cardiovascular event, defined as a composite outcome comprised of the first occurrence after randomization of any of the following: myocardial infarction, stroke, or hospitalization for heart failure, and all-cause mortality
Conditions Studied
Interventions
- DRUG Metoprolol Succinate
- DRUG Carvedilol
Study Locations (8)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
Florida
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Iowa
- Iowa City VA Health Care System, Iowa City, IA - Iowa City
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Minnesota
- Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
New Mexico
- New Mexico VA Health Care System, Albuquerque, NM - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,540 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
What NCT05931276 shows while recruiting
NCT05931276 is an interventional study that assigns participants to a tested intervention. Its 2,540 participants enrollment target places it among the larger protocols in the corpus, above the 804-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (216% higher).
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Metoprolol Succinate is the first listed.
NCT05931276 lists 8 locations in 8 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT05931276 about?
NCT05931276 is a clinical study titled "CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes". The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-...
What is the current status of trial NCT05931276?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,540 participants. The study started on 2024-05-22. Estimated completion is 2028-12-31.
What conditions does trial NCT05931276 study?
This clinical trial studies the following conditions: End Stage Renal Disease, End-Stage Kidney Disease.
What interventions are being tested in trial NCT05931276?
The interventions under investigation include: Metoprolol Succinate (DRUG), Carvedilol (DRUG).
Who is sponsoring clinical trial NCT05931276?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05931276 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05931276's enrollment target sits among peer trials
2,540 3rd of 86 higher than 84 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
COMPLETED · Phase 3
-
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
COMPLETED · Phase 3
-
Prevention of Kidney Transplant Rejection
COMPLETED · Phase 3
-
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI